Dr. Morgans discusses first-line therapy options for mCRPC and her approach to deciding between different treatment options.
Alicia Morgans, MD, MPH: The first-line options for treatment of metastatic CRPC [castration-resistant prostate cancer] are numerous, and we make our decisions based on the treatments the patient has had prior, either for nonmetastatic CRPC or for metastatic hormone-sensitive prostate cancer.
For example, patients who have had treatment with intensified ADT [androgen deprivation therapy] for metastatic hormone-sensitive prostate cancer with abiraterone, enzalutamide, or apalutamide should receive a different approach for metastatic CRPC. Usually, it’s going to be a docetaxel chemotherapy and an ADT combination in that first-line setting. If a patient has had docetaxel in the metastatic hormone-sensitive setting, they would typically proceed with a shift in the mechanism of action to treatment with ADT plus abiraterone or enzalutamide.
For patients who have had treatment for nonmetastatic CRPC, we only have those AR [androgen receptor]–targeted agents as options for intensification with our ADT, and those patients typically get treatment with chemotherapy. It’s important to remember that there are other options; for patients who have relatively slowly progressing and asymptomatic disease, sipuleucel-T is an option. For patients who have DRD alterations, they could potentially get treatment with olaparib if they had previous treatment with an AR-targeted treatment combination with ADT. Finally, if patients have significant bone metastases and pain, they could even get treatment with radium.
There are a lot of options, and we make our treatment decisions for first-line metastatic CRPC based on the combinations of therapies the patient has had in the past.
Transcript edited for clarity.
A 70-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer
May 2017
Initial presentation
A 70-year-old man presents with nocturia and decreased appetite
Clinical workup
Treatment
December 2017
November 2018
January 2019
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
Dehumanizing Language is a Top Culprit in Prostate Cancer Research
February 7th 2024In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the findings from her analysis of the Language of Respect guidelines adopted by the American Society of Clinical Oncology and how well they are followed in prostate cancer abstracts.
Read More
Significance of Early Genetic Testing in HRR-Mutated mCRPC Highlighted by Real-World Observations
January 26th 2024Individuals diagnosed with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) receiving olaparib face a critical requirement for timely and consistent genetic testing to enhance treatment outcomes.
Read More